80 to 84-year-olds invited for vaccination sooner Starting tomorrow, the first people in the age group from 80-84 years in the Netherlands will receive an invitation from RIVM for a COVID-19 vaccination.
New variants disrupt plans In the past week, from 27 January to 2 February, 28,628 people in the Netherlands reportedly tested positive for COVID-19, a 20% decrease compared to the week of 20 to 26 January.
One person died shortly after COVID-19 vaccination The Pharmacovigilance Centre Lareb announced today that the centre had received a report of death shortly after receiving the Pfizer/BioNTech COVID-19 vaccination in the Netherlands.
Nationwide assessment of SARS-CoV-2 laboratories: very high quality The vast majority of the laboratories analysing COVID-19 tests are performing at the very highest standard of quality.
Major loss of healthy life years due to long-term complaints after Lyme disease The Netherlands is the first country where the burden of disease due to Lyme disease has been determined.
The number of STI tests keeps increasing The number of clients tested for sexually transmitted infections (STIs) at Dutch STI clinics has increased since 2004.
Antibiotic resistance is stable, however, more resistant bacteria are expected Over recent years, antibiotic resistance to most agents has remained stable in the Netherlands, and the use of antibiotics has slightly decreased.
Improving consumer exposure assessment to chemical substances By combining the available international knowledge, the method to assess the extent to which consumers are exposed to chemical substances via everyday products such as paint, cleaning agents and co
RIVM seeks dialogue with Industry for safe and green chemistry RIVM would like to explore possibilities to eliminate obstacles during innovation of green chemistry with industry.
European research into chemical mixtures launched EU project EuroMix (European Test and Risk Assessment Strategies for Mixtures) was launched recently.